Avadel Pharmaceuticals plc Overview
Valuation check: AVDL's ROE is -0.28%, below the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow-0.28%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Avadel Pharmaceuticals plc (AVDL) currently reports a ROE of -0.28%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Avadel Pharmaceuticals plc's ROE history and peer comparisons.
Avadel Pharmaceuticals plc's ROE of -0.28% is lower than the Healthcare sector average of 20.86%. That is roughly 101.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Avadel Pharmaceuticals plc's current -0.28% should be judged against Healthcare norms (sector average: 20.86%) and against AVDL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -0.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Avadel Pharmaceuticals plc, and consider following AVDL for alerts when major investors trade the stock.
Avadel Pharmaceuticals plc is classified in the Healthcare sector. On ROE, it currently shows -0.28% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AVDL with unrelated industries.
